Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
0(0%)
Results Posted
63%(5 trials)

Phase Distribution

Ph phase_1
2
25%
Ph phase_2
4
50%
Ph phase_3
2
25%

Phase Distribution

2

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
2(25.0%)
Phase 2Efficacy & side effects
4(50.0%)
Phase 3Large-scale testing
2(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

8 of 8 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(8)

Detailed Status

Completed8

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (25.0%)
Phase 24 (50.0%)
Phase 32 (25.0%)

Trials by Status

completed8100%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_2

A Study to Evaluate Abicipar Pegol for Safety and Treatment Effect in Participants With Neovascular Age-related Macular Degeneration (AMD)

NCT03539549
completedphase_3

Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration

NCT02462486
completedphase_3

A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration

NCT02462928
completedphase_1

Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Japanese Patients With Neovascular AMD

NCT03335852
completedphase_1

Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Patients With Neovascular AMD

NCT02859766
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT03539549Phase 2

A Study to Evaluate Abicipar Pegol for Safety and Treatment Effect in Participants With Neovascular Age-related Macular Degeneration (AMD)

Completed
NCT02462486Phase 3

Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration

Completed
NCT02462928Phase 3

A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration

Completed
NCT03335852Phase 1

Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Japanese Patients With Neovascular AMD

Completed
NCT02859766Phase 1

Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Patients With Neovascular AMD

Completed
NCT02181504Phase 2

A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration

Completed
NCT02181517Phase 2

A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration

Completed
NCT02186119Phase 2

A Study of Abicipar Pegol in Patients With Diabetic Macular Edema

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8